Review of the acetylcholinesterase inhibitor galanthamine

Expert Opinion on Investigational Drugs

Volumn 9, Issue 10, 2000, Pages 2393-2402

  Sramek, J J ^a   Frackiewicz, E J ^a   Cutler, N R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

Alzheimer's disease; Galantamine; Galanthamine

Indexed keywords

APOMORPHINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NICOTINIC RECEPTOR; P 11012; P 11149; PLACEBO; POSTSYNAPTIC RECEPTOR; PRESYNAPTIC RECEPTOR; RIVASTIGMINE; SABELUZOLE; TACRINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; FEMALE; HUMAN; INSOMNIA; MALE; MOUSE; MUSCLE CRAMP; NAUSEA; NONHUMAN; PARALYSIS; PLANT; RANDOMIZED CONTROLLED TRIAL; RAT; SENILE DEMENTIA; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 0033815406     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.10.2393     Document Type: Article

References (62)

1. Aging brain, aging mind
2. Amyloid beta-protein and the genetics of Alzheimer's disease
3. Alzheimer neurofibrillary lesions: Molecular nature and potential roles of different components
4. The cortical neuritic dystrophy of Alzheimer's disease: Nature significance and possible pathogenesis
5. Free radical formation in autopsy samples of Alzheimer and control cortex
6. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease
7. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy
8. Correlation of cholinergic abnormalities with senile plaques and mental scores in senile dementia
9. Perforant pathway changes and the memory impairment of Alzheimer's disease
10. Lecithin for dementia and cognitive impairment
11. Effects of xanomelin, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease
12. Nicotine patches in Alzheimer's disease: Pilot study on learning, memory and safety
13. The Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease
14. The Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study
15. A randomized trial evaluating the efficacy and safety of ENA-713, a new acetylcholinesterase inhibitor in patients with mild to moderately severe Alzheimer's disease. ENA-713 (rivastigmine tartrate) B352 Study Group
16. The pharmacology of Galanthamine and its analogues
17. Reminyl approved in second market
18. Galanthamine Hydrobromide: Interim Results of a Group Comparative, Placebo-controlled Study of Efficacy and Safety in Patients with a Diagnosis of Senile Dementia of the Alzheimer Type
19. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution
20. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
21. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition
22. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agents
23. Galanthamine: Pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice
24. Galanthamine, an acetylcholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice
25. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
26. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: Selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase
27. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
28. Inhibition of acetylcholinesterase activity in human brian tissue and erthrocytes by galanthamine, physostigmine and tacrine
29. Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease
30. RBC Cholinesterase inhibition: A useful surrogate marker for cholinesterase inhibitor activity in Alzheimer's disease therapy?
31. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine
32. Effect of benactyzine and galanthamine on behavioral effects of apomorphine in rats
33. D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats
34. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats
35. A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice
36. Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice
37. THA does not affect sleep or EEG spectral power in Alzheimer's disease
38. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep
39. Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials
40. Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients
41. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans
42. The Galanthamine USA-1 Study Group. Galantamine in AD. A6-month randomized, placebo-controlled trial with a 6-month extension
43. Galanthamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD
44. Toxicity of the combination preparation nivalin-P
45. Preclinical and clinical studies on galanthamine (G) for Alzheimer's disease treatment
46. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans
47. Cholinesterase inhibition for Alzheimer's disease
48. Rivastigmine: A review of its use in Alzheimer's disease
49. Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
50. Neuromediator mechanisms of regulating immune reactions in schizophrenics
51. Galanthamine hydrobromide in mania
52. Correction of apathetic-abulic manifestations of schizophrenia withcholinotropic drugs
53. Invited Review Cholinesterase Inhibitors for Alzheimer's disease therapy: From tacrine to future applications
54. Allosteric modulation of Torpedo nicotinic acetycholine receptor ion channel activity by noncompetitive agonists
55. Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y
56. CNS nicotine receptors. Possible therapeutic targets in neurodegernative disorders
57. Stimulation of 4B2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity
58. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group
59. Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
60. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
61. Cholinesterase Inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology